Immobilizing A Moving Target: CAR T Cells Hit CD22.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31266831.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1649.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A key mechanism of resistance to chimeric antigen receptor-modified T cells (CAR-T) is loss or downregulation of target antigens. Low antigen expression on cancer cells prevents full CAR-T-cell activation and persistence. Pharmacologic modulation of target antigen expression offers a novel therapeutic strategy to drive more potent and durable responses.<i>See related article by Ramakrishna et al., p. 5329</i>.
Medical subject headings
- Immunotherapy, Adoptive
- Receptors, Antigen, T-Cell